SLEEP DEPRIVATION EEG & HMPAO-SPECT IN DEPRESSION

描述（改编自申请人摘要）： 建议的一系列调查是为了更好地了解 多导睡眠图分析睡眠剥夺的抗抑郁作用 (PSG)在一个晚上的PSD之前和之后， 正常对照者 该项目的第二个目的是分析SPECT 这些受试者的脑血流量（CBF）数据与 临床变化。 研究人员预测：1）抑郁反应者将 显示快速眼动潜伏期增加，慢波睡眠增加， PSD后睡眠效率增加; 2）反应者CBF异常 在PSD之后，分布将变得不那么异常，并且3） 这些变化将与临床反应的强度相关。 受试者将由身体健康的男性和女性组成，诊断为 重度抑郁症（单相），基线17项汉密尔顿抑郁评分 量表（HDRS-17）> 16。 正常对照组的年龄和性别将匹配。 排除标准包括其他精神疾病;妊娠; 可能因SD而加重的疾病;睡眠障碍;不规律 睡眠周期;神经或循环系统疾病，可能会影响 脑电图（EEG）或SPECT;以及最近使用的物质， 可能影响睡眠模式、脑电图和/或SPECT。 受试者将经历一个适应夜、一个基线夜、一个PSD夜， 以及在睡眠实验室进行标准记录的“恢复”之夜 蒙太奇 将使用Delta Pass系统（周期-振幅）分析数据 分析。）受试者将在基线期间接受HMPAO脑SPECT检查 下午的PSD 主观和临床医生管理的情绪， 抑郁评定量表将在标准时间进行管理， 基线和恢复日以及PSD夜间。 该研究采用3 × 2混合设计，分为3组（抑郁反应者， 抑郁症无应答者和对照组）和2种情况（基线和 PSD之后）。修改后的HDRS-17（例如，省略项目4-6（睡眠） 和16（重量损失）> 30%以下PSD将被用作标准 临床反应。 将通过多变量分析PSG和SPECT数据 方差分析

DESCRIPTION (Adapted from applicant's abstract): The primary purpose of the proposed series of investigations is to gain better understanding of the antidepressant effects of sleep deprivation by analyzing polysomnography (PSG) before and after a night of PSD in depressed patients compared to normal controls. The secondary aim of the project involves analyzing SPECT cerebral blood flow (CBF) data in these subjects for correlations with clinical changes. The investigator predicts: 1) depressed responders will show increased rapid eye movement latency, increased slow wave sleep, and increased sleep efficiency following PSD; 2) responders' abnormal CBF distribution will become less abnormal after PSD and 3) the magnitude of such changes will correlate with the intensity of clinical response. Subjects will consist of physically healthy men and women diagnosed with major depression (unipolar) with baseline 17-item Hamilton Depression Rating Scale (HDRS-17) > 16. Normal controls will be matched for age and gender. Exclusion criteria include other psychiatric disorders; pregnancy; conditions which might be exacerbated by SD; sleep disorders; irregular sleep cycle; neurological or circulatory conditions which could affect electroencephalography (EEG) or SPECT; and recent use of substances which could affect sleep pattern, EEG, and/or SPECT. Subjects will undergo an adaptation night, a baseline night, a night of PSD, and a "recovery" night in the sleep laboratory with standard recording montage. Data will be analyzed with the Delta Pass system (period-amplitude analysis.) Subjects will undergo cerebral SPECT with HMPAO during baseline and PSD afternoons. Subjective and clinician-administered mood and depression rating scales will be administered at standard times during baseline and recovery days and during the PSD night. The study, a 3 X 2 mixed design, has 3 groups (depressed responders, depressed nonresponders, and controls) and 2 conditions (baseline and following PSD.) A drop in modified HDRS-17 (e.g., omitting items 4-6 (sleep) and 16 (weight loss) > 30 percent following PSD will be used as a criterion for clinical response. PSG and SPECT data will be analyzed by multivariance analysis of variance.